Technical Analysis for CERS - Cerus Corporation

Grade Last Price % Change Price Change
F 1.89 5.59% 0.10
CERS closed up 5.59 percent on Thursday, March 28, 2024, on 69 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 5.59%
NR7 Range Contraction 5.59%
Inside Day Range Contraction 5.59%
Wide Bands Range Expansion 5.59%
Oversold Stochastic Weakness 5.59%
Outside Day Range Expansion 8.62%
Wide Bands Range Expansion 8.62%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 15 hours ago
10 DMA Resistance about 17 hours ago
Rose Above 10 DMA about 17 hours ago
Up 5% about 17 hours ago
Rose Above Previous Day's High about 17 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cerus Corporation Description

Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. Its INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; and INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion. The company is also developing INTERCEPT Blood System for red blood cells, which is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets its platelet and plasma systems through its direct sales force and distributors primarily in Europe, the Commonwealth of Independent States, and the Middle East. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Coronavirus Hematology Medical Products Viruses Blood Transfusion Medicine Blood Cells Platelet Red Blood Cell Coagulation System Blood Products Blood Transfusion Fusion Products Whole Blood

Is CERS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.08
52 Week Low 1.21
Average Volume 1,789,569
200-Day Moving Average 1.96
50-Day Moving Average 2.06
20-Day Moving Average 2.02
10-Day Moving Average 1.88
Average True Range 0.16
RSI (14) 44.44
ADX 11.53
+DI 23.33
-DI 21.63
Chandelier Exit (Long, 3 ATRs) 2.10
Chandelier Exit (Short, 3 ATRs) 2.20
Upper Bollinger Bands 2.40
Lower Bollinger Band 1.64
Percent B (%b) 0.33
BandWidth 37.35
MACD Line -0.09
MACD Signal Line -0.06
MACD Histogram -0.0266
Fundamentals Value
Market Cap 342.46 Million
Num Shares 181 Million
EPS -0.27
Price-to-Earnings (P/E) Ratio -7.00
Price-to-Sales 2.78
Price-to-Book 8.88
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.07
Resistance 3 (R3) 2.06 1.98 2.04
Resistance 2 (R2) 1.98 1.94 1.99 2.03
Resistance 1 (R1) 1.94 1.91 1.96 1.95 2.02
Pivot Point 1.86 1.86 1.88 1.87 1.86
Support 1 (S1) 1.82 1.82 1.84 1.83 1.76
Support 2 (S2) 1.74 1.79 1.75 1.75
Support 3 (S3) 1.70 1.74 1.74
Support 4 (S4) 1.71